Results 21 to 30 of about 7,770 (204)
Highly effective treatment options for rheumatoid arthritis afforded by the availability of biosimilars [PDF]
Exploration of Musculoskeletal DiseasesBiosimilars are biologic products that provide equal mechanisms and efficacy to that of their original biologic references. This paper aims to provide a comprehensive overview of the numerous ways biosimilars are improving care for individuals living ...
Leticia A. Shea, Jamshaid S. Ahmed
doaj +1 more source
Biomolecules, 2019 Physician awareness and perceptions towards biosimilars are important factors in their adoption to clinical practice. Our objectives were to assess levels of knowledge and attitudes towards biosimilars and key policies on their use among Russian ...
Dmitry Karateev, Natalia Belokoneva
doaj +1 more source
Switching Among Biosimilars: A Review of Clinical Evidence
Frontiers in Pharmacology, 2022 Biological medicines have improved patients’ outcomes, but their high costs may limit access. Biosimilars, alternatives that have demonstrated high similarity in terms of quality, safety, and efficacy to an already licensed originator biological product,
Eleonora Allocati +6 more
doaj +1 more source
Biosimilar: what it is not [PDF]
British Journal of Clinical Pharmacology, 2015 A biosimilar is a high quality biological medicine shown to be in essence the same as an original product. The European Medicines Agency (EMA) paved the way in the regulatory arena by creating a safeguarding framework for the development of biosimilars.
openaire +2 more sources
Pharmaceuticals, 2021 The aim of this study is to evaluate the effect of the introduction of biosimilars in Bulgaria on the prices and utilization of biologic disease modifying antirheumatic drugs (bDMARD).
Konstantin Tachkov +3 more
doaj +1 more source
Tendering and biosimilars: what role for value-added services?
Journal of Market Access & Health Policy, 2020 Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and
Steven Simoens, Raymond Cheung
doaj +1 more source
Journal of Oncology Practice, 2017 Biosimilar therapeutic proteins in oncology offer the potential to decrease costs while providing safety and efficacy profiles consistent with their respective reference or originator products. Biosimilars have a number of important differences from generic small-molecule drugs, including manufacturing processes that are unique from their reference ...
openaire +2 more sources
JAAD International, 2020 Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use.
Arnon D. Cohen, MD, MPH, PhD +8 more
doaj +1 more source
Resolving Heterogeneity of Targeted Lipid Nanoparticles Through Solution‐Based Biophysical Analyses
Advanced Materials, EarlyView.AF4‐UV‐DLS‐MALS‐SAXS resolves previously inaccessible targeted lipid nanoparticle (tLNP) subpopulations that differ in size, shape, and composition. Correlation of subpopulation‐resolved biophysical properties with in vivo RNA delivery reveals that targeted placental transfection is associated with distinct tLNP subpopulations rather than ensemble ...
Hannah C. Geisler +14 more
wiley +1 more source
Pharmacological Research, 2019 Biotechnologicals are an invaluable resource in the treatment of patients with inflammatory rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However, they are the main driver for increase in direct costs and represent a significant economic burden to healthcare systems worldwide.
Araújo, Filipe C. +2 more
openaire +3 more sources